Biodistribution and radiation dosimetry of LMI1195: First-in-human study of a novel 18F-labeled tracer for imaging myocardial innervation

Journal of Nuclear Medicine

Volumn 55, Issue 9, 2014, Pages 1445-1451

  Sinusas, Albert J ^a   Lazewatsky, Joel ^b   Brunetti, Jacqueline ^c   Heller, Gary ^d   Srivastava, Ajay ^a   Liu, Yi Hwa ^a   Sparks, Richard ^e   Puretskiy, Andrey ^e   Lin, Shu Fei ^a   Crane, Paul ^b   Carson, Richard E ^a   Lee, L Veronica ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b A Subsidiary of Lantheus Holdings   (United States)

^c Holy Name Medical Center   (United States)

^d MORRISTOWN MEDICAL CENTER   (United States)

^e CDE Dosimetry Services Inc   (United States)

Author keywords

Biodistribution; Dosimetry; Myocardium; Positron emission tomography; Sympathetic imaging

Indexed keywords

FLUORINE 18; N [3 BROMO 4 (3 18F FLUORO PROPOXY) BENZYL] GUANIDINE; RADIOPHARMACEUTICAL AGENT; TRACER; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; FLUORINE; FLUOROBENZENE; GUANIDINE DERIVATIVE; N (3 BROMO 4 (3 (18F)FLUORO PROPOXY)BENZYL)GUANIDINE; N-(3-BROMO-4-(3-(18F)FLUORO-PROPOXY)BENZYL)GUANIDINE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BLADDER; BLOOD PRESSURE; BODY IMAGE; CARDIAC IMAGING; CLINICAL ARTICLE; DOSE RESPONSE; DOSIMETRY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FEMALE; HEART MUSCLE; HEART RATE; HUMAN; IN VIVO STUDY; KINETICS; LIVER; LUNG; MALE; MULTICENTER STUDY; NERVE ENDING; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; RADIATION ABSORPTION; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIOACTIVITY; SINGLE DRUG DOSE; SYMPATHETIC TONE; BIODISTRIBUTION; HEART; INNERVATION; RADIOMETRY; SCINTISCANNING; SYMPATHETIC IMAGING; TISSUE DISTRIBUTION;

BIODISTRIBUTION; DOSIMETRY; MYOCARDIUM; POSITRON EMISSION TOMOGRAPHY; SYMPATHETIC IMAGING;

ADULT; FEMALE; FLUORINE RADIOISOTOPES; FLUOROBENZENES; GUANIDINES; HEART; HUMANS; MALE; RADIOMETRY; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 84907011209     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.114.140137     Document Type: Article

References (29)

1. Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults - a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119:1977-2016.
2. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics: 2008 update - a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117: e25-e146.
3. Rundqvist B, Elam M, Bergmann-Sverrisdottir Y, Eisenhofer G, Friberg P. Increased cardiac adrenergic drive precedes generalized sympathetic activation in human heart failure. Circulation. 1997;95:169-175.
4. Eisenhofer G, Friberg P, Rundqvist B, et al. Cardiac sympathetic nerve function in congestive heart failure. Circulation. 1996;93:1667-1676.
5. Beau SL, Saffitz JE. Transmural heterogeneity of norepinephrine uptake in failing human hearts. J Am Coll Cardiol. 1994;23:579-585.
6. Böhm M, La Rosee K, Schwinger RH, Erdmann E. Evidence for reduction of norepinephrine uptake sites in the failing human heart. J Am Coll Cardiol. 1995;25:146-153.
7. Brush JE Jr, Eisenhofer G, Garty M, et al. Cardiac norepinephrine kinetics in hypertrophic cardiomyopathy. Circulation. 1989;79:836-844.
8. Carrió I, Cowie MR, Yamazaki J, Udelson J, Camici PG. Cardiac sympathetic imaging with mIBG in heart failure. JACC Cardiovasc Imaging. 2010;3:92-100.
9. Higuchi T, Schwaiger M. Noninvasive imaging of heart failure: neuronal dysfunction and risk stratification. Heart Fail Clin. 2006;2:193-204.
10. Tobes MC, Jaques S Jr, Wieland DM, Sisson JC. Effect of uptake-one inhibitors on the uptake of norepinephrine and metaiodobenzylguanidine. J Nucl Med. 1985;26:897-907.
11. Jacobson AF, Senior R, Cerqueira MD, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure: results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol. 2010;55: 2212-2221.
12. Katoh S, Shishido T, Kutsuzawa D, et al. Iodine-123-metaiodobenzylguanidine imaging can predict future cardiac events in heart failure patients with preserved ejection fraction. Ann Nucl Med. 2010;24:679-686.
13. Tamaki S, Yamada T, Okuyama Y, et al. Cardiac iodine-123 metaiodobenzylguanidine imaging predicts sudden cardiac death independently of left ventricular ejection fraction in patients with chronic heart failure and left ventricular systolic dysfunction: results from a comparative study with signal-averaged electrocardiogram, heart rate variability, and QT dispersion. J Am Coll Cardiol. 2009;53:426-435.
14. Fallavollita JA, Heavey BM, Luisi AJ Jr, et al. Regional myocardial sympathetic denervation predicts the risk of sudden cardiac arrest in ischemic cardiomyopathy. J Am Coll Cardiol. 2014;63:141-149.
15. Yu M, Bozek J, Lamoy M, et al. Evaluation of LMI1195, a novel 18F-labeled cardiac neuronal PET imaging agent, in cells and animal models. Circ Cardiovasc Imaging. 2011;4:435-443.
16. Hilton J, Yokoi F, Dannals RF, Ravert HT, Szabo Z, Wong DF. Column-switching HPLC for the analysis of plasma in PET imaging studies. Nucl Med Biol. 2000; 27:627-630.
17. Siegel JA, Thomas SR, Stubbs JB, et al. MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med. 1999;40: 37S-61S.
18. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023-1027.
19. Food and Drug Administration. Guidance for Industry: Developing Medical Imaging Drug and Biological Products - Part 1: Conducting Safety Assessments. FDA.gov. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidance/ucm078930.pdf. June 2004. Accessed June 24, 2014.
20. International Commission on Radiological Protection (ICRP). Recommendations of the International Commission on Radiological Protection. ICRP publication 26. Oxford, U.K.: Pergamon Press; 1977.
21. International Commission on Radiological Protection (ICRP). 1990 Recommendations of the International Commission on Radiological Protection. ICRP publication 60. Oxford, U.K.: Pergamon Press; 1991.
22. International Commission on Radiological Protection (ICRP). Basic Anatomical and Physiological Data for use in Radiological Protection: The Skeleton. ICRP publication 70. Oxford, U.K.: Pergamon Press; 1994.
23. International Commission on Radiological Protection (ICRP). Report of the Task Group on Reference Man. ICRP publication 23. Oxford, U.K.: Pergamon Press; 1975.
24. Loevinger RBT, Watson EE. MIRD Primer for Absorbed Dose Calculations. New York, NY: Society of Nuclear Medicine; 1991.
25. Loening AM, Gambhir S. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging. 2003;2:131-137.
26. International Commission on Radiological Protection (ICRP). Radiation Dose to Patients from Radiopharmaceuticals (Addendum 2 to ICRP Publication 53). ICRP publication 80. Oxford, U.K.: Pergamon Press; 1999.
27. Yu M, Bozek J, Lamoy M, et al. LMI1195 PET imaging in evaluation of regional cardiac sympathetic denervation and its potential role in antiarrhythmic drug treatment. Eur J Nucl Med Mol Imaging. 2012;39:1910-1919.
28. Thackeray JT, Bengel FM. Assessment of cardiac autonomic neuronal function using PET imaging. J Nucl Cardiol. 2013;20:150-165.
29. Chen J, Folks RD, Verdes L, Manatunga DN, Jacobson AF, Garcia EV. Quantitative I-123 mIBG SPECT in differentiating abnormal and normal mIBG myocardial uptake. J Nucl Cardiol. 2012;19:92-99.